share_log

Pfizer | DEFA14A: Others

Pfizer | DEFA14A: Others

輝瑞 | DEFA14A:其他
SEC announcement ·  04/11 11:00
Moomoo AI 已提取核心訊息
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third party was involved in the filing. The company has confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.
Pfizer Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) as part of its proxy statement schedule 14A, in accordance with Section 14(a) of the Securities Exchange Act of 1934. The materials were submitted by Pfizer as the registrant, indicating that no third party was involved in the filing. The company has confirmed that no filing fee was required for this submission. The purpose of the filing and the contents of the additional materials have not been specified in the announcement.
根據1934年《證券交易法》第14(a)條,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託聲明附表14A的一部分。這些材料由輝瑞作爲註冊人提交,表明沒有第三方參與申報。該公司已確認本次提交不需要任何申請費。公告中沒有具體說明申報目的和補充材料的內容。
根據1934年《證券交易法》第14(a)條,輝瑞公司已向美國證券交易委員會(SEC)提交了明確的補充材料,作爲其委託聲明附表14A的一部分。這些材料由輝瑞作爲註冊人提交,表明沒有第三方參與申報。該公司已確認本次提交不需要任何申請費。公告中沒有具體說明申報目的和補充材料的內容。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息